NICE recommends Sanofi’s Dupixent(R) ▼ (dupilumab) for atopic dermatitis

The National Institute for Health and Care Excellence (NICE) has published a positive Final Appraisal Determination (FAD) recommending dupilumab, in combination with topical corticosteroids, for routine use on the National Health Service (NHS) in England for the treatment of moderate to severe atopic dermatitis in adults when they have not responded to at least one other systemic therapy (e.g. immunosuppressants) or these are contraindicated or not tolerated.

Atopic dermatitis (also known as atopic eczema) is the most common form of eczema. In the United Kingdom, approximately 1.5 million (3%) adults have atopic dermatitis. Within the general UK population, it is estimated that there are 6 adults per 100,000 with severe atopic dermatitis who may be eligible for treatment with dupilumab.

Moderate to severe atopic dermatitis is characterised by rashes often covering much of the body, and can include intense, persistent itching and skin dryness, cracking, redness, crusting, and oozing. In addition, patients can experience impaired quality of life, including disrupted sleep, and increased anxiety and depression symptoms along with their disease.

The Medicines and Healthcare products Regulatory Agency (MHRA) acknowledged the innovative nature of Dupixent[R] ▼ (dupilumab) designating it as a Promising Innovative Medicine and accelerating its journey to patients through the EAMS.

Andrew Proctor, Chief Executive at the National Eczema Society (NES) commented, “Dupilumab represents a new way of treating atopic dermatitis and we are delighted that NICE has recognised the huge challenges that some patients face in successfully managing their condition. The decision gives real hope to people who desperately need more effective treatment.”

Peter Kuiper, General Manager UK & Ireland at Sanofi Genzyme added: “Throughout the development of dupilumab we have witnessed the profound impact that atopic dermatitis can have on individuals and their families. Seeing first-hand the difference that dupilumab can make to patients’ lives has given us the drive and determination to ensure it becomes available to those who need it as quickly as possible.”